Table 3.

DNA Repair Gene Polymorphisms and Patient Survival in relation to Subtypes.

Genotype	Patients n	MST (mon)	Log-rank p value	HR (95% CI)	Adjusted HR
					p value	(95% CI) a	p value
Adenocarcinoma
OGG1
Ser/Ser	16	62	-	1.00	-	1.00	-
Ser/Cys, Cys/Cys	49	68	0.784	0.89 (0.38–2.08)	0.785	0.80 (0.29–2.26)	0.803
MUTYH
Gln/Gln	13	70		1.00		1.00
Gln/His, His/His	52	66	0.65	1.25 (0.48–3.27)	0.653	1.54 (0.44–5.36)	0.498
APEX
Asp/Asp	28	63	-	1.00	-	1.00	-
Asp/Glu, Glu/Glu	37	70	0.549	0.80 (0.39–1.67)	0.553	1.14 (0.48–2.73)	0.763
XRCC1
Arg/Arg	26	71		1.00	-	1.00	-
Arg/Gln, Gln/Gln	39	64	0.522	1.28 (0.60–2.76)	0.526	0.87 (0.35–2.20)	0.775
XRCC3
Thr/Thr	58	67	-	1.00	-	1.00	-
Thr/Met, Met/Met	7	64	0.995	1.00 (0.30–3.32)	0.995	1.32 (0.38–4.64)	0.661
Squamous Cell Carcinoma
OGG1
Ser/Ser	8	52	-	1.00	-	1.00	-
Ser/Cys, Cys/Cys	21	48	0.824	1.11 (0.43–2.88)	0.825	1.25 (0.44–3.55)	0.670
MUTYH
Gln/Gln	5	64	-	1.00	-	1.00	-
Gln/His, His/His	24	45	0.377	1.72 (0.51–5.85)	0.385	4.73 (0.51–5.85)	0.153
APEX
Asp/Asp	11	40		1.00	-	1.00	-
Asp/Glu, Glu/Glu	18	54	0.328	0.65 (0.27–1.56)	0.334	0.43 (0.14–1.32)	0.139
XRCC1
Arg/Arg	16	50		1.00	-	1.00	-
Arg/Gln, Gln/Gln	13	46	0.991	1.00 (0.42–2.37)	0.991	1.17 (0.46–2.94)	0.743
XRCC3
Thr/Thr	25	48	-	1.00	-	1.00	-
Thr/Met, Met/Met	4	13	<0.0001	9.35 (2.52–34.68)	0.001	9.05 (1.89–44.39)	0.006

^aHR adjusted for gender, age, smoking history, disease stage, metastasis, and reccurence.